An intravenous anti-FGFR2b antibody–drug conjugate that binds FGFR2b on tumor cells, is internalized, and releases an intracellular cytotoxic payload to induce tumor cell death; targeting may also attenuate FGFR2 signaling. Evaluated as monotherapy and in combination with other anticancer agents in advanced solid tumors with FGFR2b expression and/or FGFR2 amplification.
BG-C137 is an anti-FGFR2b monoclonal antibody linked to a topoisomerase-1 inhibitor. After binding FGFR2b on tumor cells and internalization, it releases the cytotoxic payload that inhibits DNA topoisomerase I, disrupting DNA replication and causing cell cycle arrest and apoptosis; target binding may also attenuate FGFR2 signaling.
NO
INDIRECT
The ADC selectively binds FGFR2b on tumor cells, is internalized, and releases a topoisomerase I–inhibiting payload that causes DNA damage and apoptosis. DNA topoisomerase I is the intracellular payload target, not the antigen used for cell targeting; topo I expression alone does not make cells directly killed by the drug.
Oral selective BCL-2 inhibitor that promotes mitochondrial apoptosis in malignant cells.
Selective BCL-2 inhibitor (BH3 mimetic) that binds the hydrophobic groove of BCL-2, neutralizing its anti-apoptotic function and restoring mitochondrial apoptosis (MOMP, cytochrome c release, caspase activation) in BCL-2–dependent malignant cells; spares BCL-XL relative to navitoclax.
YES
DIRECT
Venetoclax binds and inhibits BCL-2 (BH3 mimetic), disabling its anti-apoptotic function and freeing pro-apoptotic effectors to trigger MOMP, cytochrome c release, caspase activation, and apoptosis in BCL-2–dependent cells.
Anti-CD22 antibody-drug conjugate delivering calicheamicin to CD22+ B cells, causing DNA breaks and cytotoxicity.
Humanized anti-CD22 monoclonal antibody linked to calicheamicin; after binding CD22 on B cells and internalization, releases calicheamicin that binds the DNA minor groove, causing double-strand breaks and apoptosis in CD22-positive cells.
YES
DIRECT
The ADC binds CD22, is internalized, and releases calicheamicin inside the cell, causing DNA double-strand breaks and apoptosis in CD22-positive cells.
Also known as AMT-754, ADCE-T02 is an intravenously administered antibody-drug conjugate (ADC) targeting Tissue Factor (TF; CD142/F3) on tumor cells. After binding and internalization, it releases a cytotoxic payload to induce cancer cell death.
Monoclonal antibody targets Tissue Factor (TF/CD142) on tumor cells; after binding and internalization, the ADC releases an intracellular cytotoxic payload that kills the cancer cell.
YES
DIRECT
The ADC binds Tissue Factor (CD142) on the tumor cell, is internalized, and releases an intracellular cytotoxic payload that kills the cell (e.g., via microtubule disruption or DNA damage–induced apoptosis).
Anti-CD22 antibody-drug conjugate delivering calicheamicin to CD22+ B cells, causing DNA breaks and cytotoxicity.
Humanized anti-CD22 monoclonal antibody linked to calicheamicin; after binding CD22 on B cells and internalization, releases calicheamicin that binds the DNA minor groove, causing double-strand breaks and apoptosis in CD22-positive cells.
NO
INDIRECT
Inotuzumab ozogamicin targets CD22 on B cells, is internalized, and releases calicheamicin that binds the DNA minor groove to cause double-strand breaks and apoptosis in CD22-positive cells.